Insights on T-DXd and Emerging Research on ADCs in HR+/HER2-Low Breast Cancer

Opinion
Video

Laura Huppert, MD, and Aditya Bardia, MD, MPH, FASCO, share advice for community oncologists on the utilization of T-DXd and discuss the future outlook for antibody-drug conjugates in HR+/HER2-low breast cancer.

Related Videos
Corey Cutler, MD, MPH, and Hannah Choe, MD, experts on GVHD
Corey Cutler, MD, MPH, and Hannah Choe, MD, experts on GVHD
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
2 KOLs are featured in this program.
2 KOLs are featured in this program.
Hannah Choe, MD, an expert on GVHD
Corey Cutler, MD, MPH, an expert on GVHD
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
Related Content